Meeting
2016 Gastrointestinal Cancers Symposium
Phase II study of fixed dose-rate gamcitabine plus S-1 as second-line treatment in advanced biliary tract cancer.
Authors
Satoshi Kobayashi
Kanagawa Cancer Center, Yokohama, Japan
Satoshi Kobayashi , Kazuya Sugimori , Chigusa Morizane , Yasushi Kojima , Makoto Ueno , Manabu Morimoto , Shinichi Ohkawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000005918
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 301)
DOI
10.1200/jco.2016.34.4_suppl.301
Abstract #
301
Poster Bd #
F3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
First Author: John Ebben
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer.
First Author: Richard D. Kim
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Nab-paclitaxel plus anti–PD-1 antibody as second-line treatment for advanced biliary tract cancer: An investigator-initiated phase 2 study (NapaSinti trial).
First Author: Xiaofen Li
Poster
2022 ASCO Annual Meeting
Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
First Author: Vaibhav Sahai